Rain Oncology Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rain Oncology Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2023.
  • Rain Oncology Inc. Debt-to-equity for the quarter ending September 30, 2023 was 21.5 %, a 64% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 21.5 +8.37 +64% Sep 30, 2023
Q2 2023 20.3 +9.34 +85.5% Jun 30, 2023
Q1 2023 17.4 +8.25 +90.2% Mar 31, 2023
Q4 2022 15 +4.09 +37.5% Dec 31, 2022
Q3 2022 13.1 -0.19 -1.43% Sep 30, 2022
Q2 2022 10.9 Jun 30, 2022
Q1 2022 9.14 Mar 31, 2022
Q4 2021 10.9 Dec 31, 2021
Q3 2021 13.3 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.